Vaccine design reaches the atomic level

Science Translational Medicine

Volumn 3, Issue 91, 2011, Pages

  Kwong, Peter D ^a   Shapiro, Lawrence ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN;

BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; COMBINATORIAL CHEMISTRY; DRUG DESIGN; DRUG SCREENING; GENETIC VARIABILITY; GENOMICS; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; ANIMAL; IMMUNITY; IMMUNOLOGY; NOTE;

ANIMALS; ANTIGENS, BACTERIAL; DRUG DESIGN; HUMANS; IMMUNITY; NEISSERIA MENINGITIDIS;

EID: 79960343541     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002807     Document Type: Review

References (36)

1. B. M. Andersen, Mortality in meningococcal infections. Scand. J. Infect. Dis. 10, 277-282 (1978).
2. D. A. Caugant, M. C. Maiden, Meningococcal carriage and disease - Population biology and evolution. Vaccine 27, (Suppl 2), B64-B70 (2009).
3. E. C. Gotschlich, T. Y. Liu, M. S. Artenstein, Human immunity to the meningococcus 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 129, 1349-1365 (1969).
4. R. Rappuoli, Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 19, 2319-2322 (2001).
5. M. M. Giuliani, J. Adu-Bobie, M. Comanducci, B. Aricò, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Serruto, D. Veggi, M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E. Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli, M. Pizza, A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U.S.A. 103, 10834-10839 (2006).
6. R. Rappuoli, Reverse vaccinology. Curr. Opin. Microbiol. 3, 445-450 (2000).
7. M. Pizza, V. Scarlato, V. Masignani, M. M. Giuliani, B. Aricò, M. Comanducci, G. T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C. L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D. W. Hood, A. C. Jeffries, N. J. Saunders, D. M. Granoff, J. C. Venter, E. R. Moxon, G. Grandi, R. Rappuoli, Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816-1820 (2000).
8. V. P. Ferreira, M. K. Pangburn, C. Cortés, Complement control protein factor H: The good, the bad, and the inadequate. Mol. Immunol. 47, 2187-2197 (2010).
9. V. Masignani, M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, D. Serruto, D. Litt, S. Kroll, J. A. Welsch, D. M. Granoff, R. Rappuoli, M. Pizza, Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197, 789-799 (2003).
10. D. M. Granoff, Review of meningococcal group B vaccines. Clin. Infect. Dis. 50, (suppl. 2), S54-S65 (2010).
11. J. M. Pearce, Salk and Sabin: Poliomyelitis immunisation. J. Neurol. Neurosurg. Psychiatry 75, 1552 (2004).
12. M. Hampl, Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines. Minerva Med. 98, 121-130 (2007).
13. M. Scarselli, B. Aricò, B. Brunelli, S. Savino, F. Di Marcello, E. Palumbo, D. Veggi, L. Ciucchi, E. Cartocci, M. J. Bottomley, E. Malito, P. Lo Surdo, M. Comanducci, M. M. Giuliani, F. Cantini, S. Dragonetti, A. Colaprico, F. Doro, P. Giannetti, M. Pallaoro, B. Brogioni, M. Tontini, M. Hilleringmann, V. Nardi-Dei, L. Banci, M. Pizza, R. Rappuoli, Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3, 91ra62 (2011).
14. K. L. Seib, F. Oriente, J. Adu-Bobie, P. Montanari, F. Ferlicca, M. M. Giuliani, R. Rappuoli, M. Pizza, I. Delany, Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine 28, 2416-2427 (2010).
15. S. Choe, M. J. Bennett, G. Fujii, P. M. Curmi, K. A. Kantardjieff , R. J. Collier, D. Eisenberg, The crystal structure of diphtheria toxin. Nature 357, 216-222 (1992).
16. J. M. Hogle, M. Chow, D. J. Filman, Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229, 1358-1365 (1985).
17. L. Cendron, D. Veggi, E. Girardi, G. Zanotti, Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086). Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67, 531-535 (2011).
18. T. Zhou, L. Xu, B. Dey, A. J. Hessell, D. Van Ryk, S. H. Xiang, X. Yang, M. Y. Zhang, M. B. Zwick, J. Arthos, D. R. Burton, D. S. Dimitrov, J. Sodroski, R. Wyatt, G. J. Nabel, P. D. Kwong, Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007).
19. B. Dey, K. Svehla, L. Xu, D. Wycuff, T. Zhou, G. Voss, A. Phogat, B. K. Chakrabarti, Y. Li, G. Shaw, P. D. Kwong, G. J. Nabel, J. R. Mascola, R. T. Wyatt, Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5, e1000445 (2009).
20. R. Acharya, E. Fry, D. Stuart, G. Fox, D. Rowlands, F. Brown, The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. Nature 337, 709-716 (1989).
21. R. Mateo, E. Luna, V. Rincón, M. G. Mateu, Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines. J. Virol. 82, 12232-12240 (2008).
22. B. E. Correia, Y. E. Ban, M. A. Holmes, H. Xu, K. Ellingson, Z. Kraft, C. Carrico, E. Boni, D. N. Sather, C. Zenobia, K. Y. Burke, T. Bradley-Hewitt, J. F. Bruhn-Johannsen, O. Kalyuzhniy, D. Baker, R. K. Strong, L. Stamatatos, W. R. Schief, Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116-1126 (2010).
23. G. Ofek, F. J. Guenaga, W. R. Schief, J. Skinner, D. Baker, R. Wyatt, P. D. Kwong, Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. U.S.A. 107, 17880-17887 (2010).
24. G. Ofek, M. Tang, A. Sambor, H. Katinger, J. R. Mascola, R. Wyatt, P. D. Kwong, Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737 (2004).
25. G. Ofek, K. McKee, Y. Yang, Z. Y. Yang, J. Skinner, F. J. Guenaga, R. Wyatt, M. B. Zwick, G. J. Nabel, J. R. Mascola, P. D. Kwong, Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J. Virol. 84, 2955-2962 (2010).
26. J. S. McLellan, B. E. Correia, M. Chen, Y. Yang, B. S. Graham, W. R. Schief, P. D. Kwong, Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409, 853-866 (2011).
27. P. D. Kwong, G. J. Nabel, P. Acharya, J. C. Boyington, C. Hood, L. Chen, A. Kim, L. Kong, Y. D. Kwon, S. Majeed, J. McLellan, G. Ofek, M. Pancera, M. Sastry, A. C. Shah, J. Stuckey, T. Zhou, Eds., Structural Biology and the Design of Effective Vaccines Against HIV-1 and Other Viruses, vol. III (Humana Press, Totwa, New Jersey, 2011).
28. X. Yang, V. Tomov, S. Kurteva, L. Wang, X. Ren, M. K. Gorny, S. Zolla-Pazner, J. Sodroski, Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J. Virol. 78, 12975-12986 (2004).
29. L. Wu, T. Zhou, Z. Y. Yang, K. Svehla, S. O'Dell, M. K. Louder, L. Xu, J. R. Mascola, D. R. Burton, J. A. Hoxie, R. W. Doms, P. D. Kwong, G. J. Nabel, Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J. Virol. 83, 5077-5086 (2009).
30. R. Pantophlet, I. A. Wilson, D. R. Burton, Hyperglycosylated mutants of human immumodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77, 5889-5901 (2003).
31. X. Wu, Z. Y. Yang, Y. Li, C. M. Hogerkorp, W. R. Schief, M. S. Seaman, T. Zhou, S. D. Schmidt, L. Wu, L. Xu, N. S. Longo, K. McKee, S. O'Dell, M. K. Louder, D. L. Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P. D. Kwong, M. Roederer, R. T. Wyatt, G. J. Nabel, J. R. Mascola, Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
32. D. R. Burton, Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706-713 (2002).
33. D. R. Burton, R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, R. T. Wyatt, HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
34. L. Chen, Y. D. Kwon, T. Zhou, X. Wu, S. O'Dell, L. Cavacini, A. J. Hessell, M. Pancera, M. Tang, L. Xu, Z. Y. Yang, M. Y. Zhang, J. Arthos, D. R. Burton, D. S. Dimitrov, G. J. Nabel, M. R. Posner, J. Sodroski, R. Wyatt, J. R. Mascola, P. D. Kwong, Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326, 1123-1127 (2009).
35. T. Zhou, I. Georgiev, X. Wu, Z. Y. Yang, K. Dai, A. Finzi, Y. D. Kwon, J. F. Scheid, W. Shi, L. Xu, Y. Yang, J. Zhu, M. C. Nussenzweig, J. Sodroski, L. Shapiro, G. J. Nabel, J. R. Mascola, P. D. Kwong, Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
36. Acknowledgments: We thank J. Stuckey for assistance with figures and G. J. Nabel and members of the structural biology and structural bioinformatics core sections of the Vaccine Research Institute for helpful discussions.